Former President Joe Biden's prostate cancer has metastasized to his bones, resulting in significant pain and physical debilitation, according to his son Hunter Biden. Despite his health struggles, Biden continues to publicly advocate on key issues, demonstrating resilience amid his battle with cancer.

Hunter Biden expressed emotional concern over his father's condition, describing the situation as very sad to witness. Joe Biden was diagnosed with an aggressive form of prostate cancer in May last year, shortly after leaving the White House.

His medical history includes skin cancer surgery and radiation therapy for prostate cancer. His family, including Jill Biden, revealed the diagnosis was shocking, especially since screening measures may have missed earlier signs.

Despite the severity, Biden remains active in public life, emphasizing his commitment to the country as he prepares to publish a memoir post-midterms.

Hunter Biden has suggested that his father, President Joe Biden, may have been affected by cancer during a recent debate, attributing his poor performance to health issues. However, medical experts assert that it is unlikely the cancer diagnosed months later had any influence on his debate conduct, casting doubt on Hunter Biden's explanation.

Hunter Biden has attributed Joe Biden’s poor debate performance to cancer, implying it may have impacted his focus or clarity. However, medical experts have dismissed this claim, stating it is unlikely that the cancer diagnosed months after the debate influenced his behavior during the event.

The controversy adds a new layer to ongoing discussions about the President’s health and cognitive state amidst political narratives.

Hunter Biden suggests that his father, President Joe Biden's, recent poor debate performance was influenced by his cancer diagnosis, though medical experts dispute this claim. The controversy has sparked discussions about health and credibility during critical political moments.

Hunter Biden recently attributed his father Joe Biden’s poor debate performance to a cancer diagnosis that came months later, raising questions about the timing and impact of the illness. Medical experts, however, have stated that it is unlikely the cancer affected Joe Biden's debate effectiveness, suggesting the explanation may be coincidental or politically motivated.

Hunter Biden has suggested that his father, President Joe Biden's, recent poor performance in a debate may have been influenced by his cancer diagnosis. However, medical experts contend it is unlikely that the cancer diagnosed months later had any impact on his debate demeanor, casting doubt on Hunter's explanation.

Hunter Biden recently attributed his father Joe Biden’s poor performance in a recent debate to his cancer diagnosis, suggesting health issues may have impacted his debate skills. However, medical experts have dismissed this explanation, stating it is unlikely that the cancer diagnosed months after the debate influenced his debate performance.

Hunter Biden has suggested that his father, Joe Biden, was affected during a recent debate due to a cancer diagnosis made months later. Medical experts, however, have indicated that it is unlikely the cancer impacted President Biden's debate performance.

The controversy raises questions about the timing and influence of health issues on political appearances.

Hernando Salcedo, an 83-year-old from Miami, was diagnosed with stage III pancreatic cancer after experiencing unexplained stomach swelling and weight loss. Facing limited treatment options and severe side effects from traditional chemotherapy, his case was considered for a clinical trial testing the RenovoCath system, a targeted chemotherapy delivery device.

This innovative approach compartmentalizes chemotherapy directly to the tumor site, significantly reducing side effects and potentially extending survival. After undergoing treatment with the RenovoCath device, Salcedo reported feeling better than he had in months, experiencing minimal side effects and maintaining a good quality of life.

His cancer has remained stable since mid-April, and he has been able to participate in family events and travel, including attending a wedding in Colombia. While experts acknowledge that stage III pancreatic cancer typically has a poor prognosis, Salcedo’s case offers promising insights into the potential benefits of localized chemotherapy techniques, with ongoing research expected to further validate these advancements.

Hernando Salcedo, an 83-year-old active grandfather, was diagnosed with Stage III pancreatic cancer after experiencing unexplained stomach swelling. Traditionally, such a diagnosis has a bleak outlook, with most patients surviving only months.

Salcedo, however, became part of an innovative clinical trial at the Miami Cancer Institute that used a specialized chemotherapy delivery device, the RenovoCath system, which targets the tumor more precisely and reduces side effects. Unlike traditional chemotherapy, which affects the entire body and often causes severe side effects, the catheter method isolates the drug delivery to the tumor site.

Salcedo received this treatment for four months, feeling markedly better and experiencing no nausea or pain. His condition stabilized, and he has enjoyed quality time with family, including traveling and celebrating milestones.

This approach has extended his life beyond typical expectations, demonstrating promising results for future pancreatic cancer treatments. More research is ongoing, and final trial data is expected in late 2027.

Hernando Salcedo, an 83-year-old in Miami, was diagnosed with advanced pancreatic cancer after experiencing unexplained stomach swelling. Conventional treatments offered limited hope due to his age and health, but he enrolled in a clinical trial testing a novel chemotherapy delivery device, RenovoCath.

This targeted approach used a catheter to deliver chemotherapy directly to the tumor site, reducing side effects and improving his quality of life. Salcedo's participation proved transformative. Unlike traditional chemotherapy, which caused severe side effects, the new method allowed him to feel well after treatments, enabling him to resume normal activities and enjoy family milestones.

One year post-diagnosis, his cancer remains stable, and he continues to experience improved health and vitality, defying typical prognosis for his stage of cancer. Experts hope ongoing research will validate this approach as a significant advancement in pancreatic cancer therapy.

Hernando Salcedo, an 83-year-old with stage III pancreatic cancer, faced a grim prognosis after traditional treatments caused severe side effects. His journey took a turn when he joined a clinical trial testing RenovoRX’s targeted chemotherapy device, RenovoCath, which delivers medication directly to tumors, reducing systemic side effects.

The trial showed promising results, with Salcedo experiencing significant quality-of-life improvements and stable cancer status after four months of treatment. This novel approach has already been cleared by the FDA and is under further study, with final results expected in late 2027.

Salcedo’s case highlights the potential of localized chemotherapy techniques to extend survival and improve life quality in patients with traditionally incurable pancreatic cancer. One year post-diagnosis, Salcedo is enjoying travel and family milestones—outcomes that were unlikely with conventional treatments, offering hope for future advances in pancreatic cancer care.

Hernando Salcedo, an 83-year-old diagnosed with stage III pancreatic cancer, faced a grim prognosis with typical survival rates of just months. After suffering severe side effects from traditional chemotherapy, he qualified for a clinical trial testing a new targeted chemotherapy delivery system called RenovoCath.

This device allows chemotherapy to be precisely administered near the tumor, reducing side effects and potentially extending survival. Salcedo's decision to participate in the trial proved transformative.

Unlike traditional treatments, he experienced minimal side effects and his cancer remained stable for over a year. His improved quality of life has enabled him to enjoy family milestones, including traveling for a wedding.

While the prognosis remains uncertain given his age, Salcedo's case highlights the promise of innovative therapies to extend life and improve well-being for pancreatic cancer patients.

Hernando Salcedo, an 83-year-old diagnosed with Stage III pancreatic cancer, faced grim survival odds with traditional treatments. After experiencing severe side effects from chemotherapy, he was offered the opportunity to participate in a cutting-edge clinical trial utilizing the RenovoCath system, which delivers chemotherapy directly to the tumor area.

The new method significantly reduced side effects and improved his quality of life, allowing him to enjoy milestones like traveling and family gatherings. Salcedo’s participation in the trial, combined with the localized delivery of chemotherapy, resulted in stable disease status a year after diagnosis, defying typical prognosis for such advanced cancer.

He reports feeling well and regaining his energy, with doctors hopeful about the treatment’s potential to extend life while maintaining quality. The trial's promising early results could pave the way for more effective pancreatic cancer therapies, with further research expected to validate these outcomes by late 2027.

Hernando Salcedo, an 83-year-old with stage III pancreatic cancer, faced a grim prognosis with traditional treatments offering limited survival and severe side effects. After his diagnosis in mid-2025, Salcedo underwent aggressive chemotherapy at the Miami Cancer Institute, which left him debilitated and in pain.

However, a clinical trial exploring a new chemotherapy delivery device provided a turning point. The RenovoCath system, designed to deliver targeted chemotherapy directly to the tumor, showed promising results, including fewer side effects and an extension of survival, according to recent trial data.

Salcedo eagerly joined the trial and received treatment with the RenovoCath system. Unlike conventional chemotherapy, which affects the entire body, this method localizes the medication to the tumor, greatly reducing adverse effects.

Following several cycles, imaging revealed stable disease, and Salcedo's quality of life improved significantly. A year after his diagnosis, his cancer remains stable, and he has regained energy, resumed walks, and participated in family celebrations, including a wedding in Colombia.

His story exemplifies how innovative clinical trials can provide hope and valuable life extension for patients with deadly cancers.